Future therapies for chronic hepatitis C

摘要: Therapy for hepatitis C has been fairly stagnant the past decade, but few years have seen major progress and evolution, beginning with approval of two HCV protease inhibitors in 2011. In spite considerable improvements response rates these agents, a need additional agents improved potency tolerability remains. Toward this goal over course just months, therapy pipeline already become crowded direct-acting antivirals, host-targeted unique interferons, all which are positioned to be part next wave therapeutic options. The ultimate push new is achieve safe straight forward yet highly effective that widely embraced readily available. Particularly among 'baby boomer' population, it predicted years, more patients currently quiescent infections will newly diagnosed, those diagnosed at increased risk long-term complications infection, thus treatment. A simple treatment paradigm necessity. This Review chronicles latest developments potential effect treatments could on delivery care infected HCV.